HK/China Healthcare Analyst (ex-Fosun Pharma)

Xinyao (Criss) Wang

Over 15 years' experience in both finance and healthcare, covering clinic operations, investment and equity research in both China and overseas.

Pre-IPO Broncus Holding Corporation - The Strength and the Concerns

Pre-IPO Hangzhou Bioer Technology - Concerns Behind the Outstanding Performance

Pre-IPO Abbisko Cayman - It Still Takes Some Time for Commercialization

Pre-IPO Medlive Technology - Here Are the Strength and the Challenges

Pre-IPO Shanghai Conant Optical - Here Are the Strength and the Concerns

Pre-IPO Guangzhou Pharmaceuticals - The Risk Points Gradually Emerged

Battle Lines Drawn As BABA Builds Out First/Last-Mile Capacity; But Who Will Fund 75+ Bn CNY CapEx?

Equity Capital Markets

Keymed Biosciences / Equity Capital Markets

<p>On April 8, 2021, <a href="https://www.smartkarma.com/entities/keymed-biosciences-inc" target="_blank" data-smartkarma-citation="entities:33011:1" rel="noopener">Keymed Biosciences Inc (KBS HK)</a> filed a prospectus with the Hong Kong Stock Exchange to apply for a main board listing. It is worth mentioning that, the major competing product, Sanofi’s Dupixent (dupilumab) was approved in China last year for the indication of moderate-to-severe atopic dermatitis (AD) in adults and was successfully included in the medical insurance catalogue in December 2020, becoming the only targeted biological agent for the treatment of moderate-to-severe AD in the catalogue. On the other hand, the core product of Keymed, CM310, was just at phase II clinical trial, far lagging behind Dupixent. Besides, the Company has no products approved for commercial sale at present. So it is not surprising that Keymed plans to go public for financing so as to accelerate the development and commercialization of the its product candidates. </p>

On April 8, 2021, Keymed Biosciences Inc (KBS HK) filed a prospectus with the Hong Kong Stock Exchange to apply for a main board listing. It is worth mentioning that, the major competing product, Sanofi’s Dupixent (dupilumab) was approved in China last year for the indication of moderate-to-severe atopic dermatitis (AD) in adults and was successfully included in the medical insurance catalogue in December 2020, becoming the only targeted biological agent for the treatment of moderate-to-severe AD in the catalogue. On the other hand, the core product of Keymed, CM310, was just at phase II clinical trial, far lagging behind Dupixent. Besides, the Company has no products approved for commercial sale at present. So it is not surprising that Keymed plans to go public for financing so as to accelerate the development and commercialization of the its product candidates. 

Pre-IPO Keymed Biosciences - Challenges Are Inevitable Despite Some Advantages on Pipeline